STRucturation of Transcript Analysis of Genes Involved in Hereditary Cancers

Last updated: March 11, 2025
Sponsor: University Hospital, Rouen
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cancer

Treatment

N/A

Clinical Study ID

NCT06861621
2022/310/OB
IDRCB : 2023-A00488-37
  • Ages > 18
  • All Genders

Study Summary

Molecular diagnosis using high throughput sequencing has become an essential part of oncogenetic care, making it possible to identify people at risk, to guide surveillance, and to direct preventive surgery and treatment. The quality of this 'precision' care depends on the quality of the interpretation of the genomic variants identified. To be usable in oncogenetics, a genomic variant must be correctly interpreted: pathogenic, benign or of uncertain significance (VSI). The impact of these DNA variants (VSI) on RNA is particularly important for interpretation. Today, due to a lack of resources, joint and systematic DNA/RNA analysis is never carried out. This has inevitably meant that a number of situations of interest have been overlooked. It is now important to go a step further and organise a visible and reliable circuit, allowing routine access to these studies for patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Over 18 years of age

  • Patients seen in oncogenetic consultations and who have given their informed consentfor genetic analysis in the context of a major predisposition to breast, ovarian ordigestive cancer.

  • Person who has read and understood the information note and does not object totaking part in the study

  • Membership of a social security scheme

Exclusion

Exclusion Criteria:

  • Minors

  • Persons deprived of their liberty or adults under guardianship or incapable ofgiving their consent

  • Failure to obtain informed consent

Study Design

Total Participants: 1000
Study Start date:
September 01, 2023
Estimated Completion Date:
April 01, 2025

Study Description

Systematic DNA/RNA analysis is never carried out using the current approach, due to a lack of resources. Strategies recommend pre-screening variants using in silico analysis, followed by RNA studies targeting variants of interest.

Connect with a study center

  • Service Oncogénétique Centre François Baclesse

    Caen, 14076
    France

    Active - Recruiting

  • Clinique de génétique médicale Guy Fontaine de l'hopital de Flandre CHRU de Lille

    Lille, 59067
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.